Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024.
“We are very pleased to have the opportunity to present our initial Phase 2 efficacy and safety data from the LUNA study at the Macula Society meeting” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. “We recently received confirmation that our abstract was accepted and we are delighted to present at a medical conference focused on groundbreaking advances in retinal and macular diseases. We look forward to sharing those data during the meeting in early February rather than before year end, as originally planned.”
Macula Society Meeting Presentation Details:
Title: Ixoberogene soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration: Preliminary Results from the Phase 2 LUNA Study
Date / Time: Thursday, February 8th, 2024 at 7:56 am PT*
Session: AMD II Neovascular Trials
Presenter: Arshad M. Khanani, M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates, Clinical Associate Professor at University of Nevada, Reno School of Medicine
Adverum Biotechnologies plans to host a conference call to discuss these data, with details to be provided at a future date. The presentation from the 47th Annual Macula Society Meeting will also be made available on Adverum’s website under News & Publications and through the following link: https://adverum.com/news-publications.
*Preliminary schedule with the exact date and time of presentation subject to change.
About Adverum Biotechnologies